Results 281 to 290 of about 3,520,446 (404)

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk

Arthritis Care &Research, Accepted Article.
Objective The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase (MMP)‐7, and serum anti‐malondialdehyde‐acetaldehyde (anti‐MAA) antibody for RA‐associated interstitial lung disease risk stratification. Methods Using a multicenter cohort of US veterans with RA, we performed a cross‐
Kelsey Coziahr, Austin M. Wheeler, Brent A. Luedders, Michael Duryee, Halie Frideres, Katherine D. Wysham, Grant W. Cannon, Gary Kunkel, Dana P. Ascherman, Paul A. Monach, Gail S. Kerr, Andreas M. Reimold, Scott M. Matson, Joshua F. Baker, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England   +16 more
wiley   +1 more source

The socioeconomic impact of inherited retinal dystrophies (IRDs) in Belgium: A cost-of-illness study. [PDF]

PLoS One
Vandersmissen I, Geers J, Denee T, Oinasmaa S, Hoeben D, Zhang X, Aydin B, Cheung S, Billiet L, Joniau I, Daly A, Simoens S, Leroy BP.   +12 more
europepmc   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, Accepted Article.
Background Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined: 1) associations between economic insecurities and PROs; 2) the impact of screening and addressing economic insecurities during ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Cost-Effectiveness of Home-Based Self-Sampling vs Clinician Sampling for Anal Precancer Screening.

JAMA Netw Open
Damgacioglu H, McAuliffe TL, Ridolfi TJ, Chiao E, Fernandez ME, Schick V, Smith JS, Brzezinski B, Nitkowski J, Deshmukh AA, Nyitray AG.   +10 more
europepmc   +1 more source

Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis. [PDF]

Lupus Sci Med
Deng L, Wang H, Yuan D, Tan C, Peng Y, Yi L, Wen Z.   +6 more
europepmc   +1 more source

New Onset of Fibromyalgia After Exposure to a Combat Environment: A Longitudinal Cohort Study

Arthritis Care &Research, Accepted Article.
Objective Traumatic life events are hypothesized to be triggers for the onset of fibromyalgia. Posttraumatic stress disorder (PTSD) is a common comorbidity of fibromyalgia. However, limited prospective data are available on the development of fibromyalgia after exposure to high magnitude stress.
Jay B. Higgs, Willie J. Hale, Casey L. Straud, Jim Mintz, Stacey Young‐McCaughan, Kimberly D. Gomes, Chelsea J. Sterne, Katrina M. Lawrence‐Wolff, Alan J. Bartholomew, Kevin M. Kelly, Douglas M. Maurer, Catherine Vriend, Brett T. Litz, Douglas E. Williamson, Alan L. Peterson, for the STRONG STAR Consortium   +15 more
wiley   +1 more source

Cost-utility analysis of acupotomy combined with epidural steroid injection for lumbosacral radiculopathy: analysis of randomized controlled trial. [PDF]

BMC Complement Med Ther
Jang S, Park TY, Lee JH, Suh HS.
europepmc   +1 more source

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐modifying Antirheumatic Drug

Arthritis Care &Research, Accepted Article.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) Methods PrismRA incorporated 19 gene expression features and 4 clinical features to assess a patient's likelihood of ...
Fenglong Xie, Timothy Beukelman, Nicholas P McCormick, Jeffrey R Curtis   +3 more
wiley   +1 more source

Cost-effectiveness analysis of tuberculosis screening in diabetic patients in China: a decision-analytic Markov model. [PDF]

Front Public Health
Song HW, Lin Y, Wan TE, Zhang CF, Pan JS.   +4 more
europepmc   +1 more source

Cost benefit analysis and the FDA: measuring the costs and benefits of drug approval under the PDUFA I-II, 1998–2005 [PDF]

Samuel DeCanio
openalex   +1 more source